Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Arixtra Should Promote Awareness of VTE: GSK
June 18, 2007
- Mr Sawai Responds to Criticisms
June 18, 2007
- JPA Concerned about Excess of Pharmacists
June 18, 2007
- GENERIC NEWS IN BRIEF
June 18, 2007
- WG Inaugurated to Predict Demand & Supply for Pharmacists
June 18, 2007
- 28 Drugs (13 APIs) Included in NHI Price List
June 18, 2007
- Sales of 23 TSE Section 1 Companies Up 2.2%
June 18, 2007
- 77 Applications for New Drugs Approved in FY2006: PMDA
June 18, 2007
- Reconsider Insurance Coverage of Long-listed Original Drugs, OTC Drug-Like Ethical Drugs: Council
June 18, 2007
- REGULATORY NEWS IN BRIEF
June 18, 2007
- R&D NEWS IN BRIEF
June 18, 2007
- Takeda Looks for Alliance, Acquisition Opportunities: President Hasegawa
June 18, 2007
- Five Medical Devices Recommended for Priority Review
June 18, 2007
- SURVEY／Metabolic Syndrome Affects 19 Mil. Japanese
June 18, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 18, 2007
- Chuikyo Starts Discussing FY2008 Drug Pricing Reform
June 11, 2007
- Combined Sales, Profits of 4 Major Generic Firms Show Double-Digit Increases
June 11, 2007
- Taiyo Yakuhin: Sales Up but Ordinary Profits Down due to Aggressive Investment
June 11, 2007
- Towa: Operating Profits Up 84% as a Result of "Reasonable Pricing Policy"
June 11, 2007
- Suzuken Launches Given Imaging's Capsule Endoscope
June 11, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…